{"filing":{"accession_number":"0001213900-26-062155","cik":"0002075320","ticker":"PLYX","company_name":"Polaryx Therapeutics, Inc.","form":"8-K","filing_date":"2026-05-28","report_date":null,"primary_document":"ea0291692-8k_polaryx.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2075320/000121390026062155/ea0291692-8k_polaryx.htm"},"events":[{"id":8488,"run_id":7449,"accession_number":"0001213900-26-062155","anchor_item_number":"7.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"The filing discloses a \"Private Placement\" announced via press release on May 28, 2026, with a Securities Purchase Agreement dated May 27, 2026 attached as Exhibit 10.1. This is a classic unregistered equity issuance to private investors. For a small-cap biotech company like Polaryx Therapeutics, a private placement is material as it signals capital raising, potential dilution to existing shareholders, and the company's liquidity position.","company_name":"Polaryx Therapeutics, Inc.","ticker":"PLYX","filing_date":"2026-05-28","form":"8-K","submitted_at":null,"items":[{"id":2399,"accession_number":"0001213900-26-062155","item_number":"7.01","item_title":"Regulation","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses a \"Private Placement\" announced via press release on May 28, 2026, with a Securities Purchase Agreement dated May 27, 2026 attached as Exhibit 10.1. This is a classic unregistered equity issuance to private investors. For a small-cap biotech company like Polaryx Therapeutics, a private placement is material as it signals capital raising, potential dilution to existing shareholders, and the company's liquidity position.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:42:51.845064+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2399,"accession_number":"0001213900-26-062155","item_number":"7.01","item_title":"Regulation","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses a \"Private Placement\" announced via press release on May 28, 2026, with a Securities Purchase Agreement dated May 27, 2026 attached as Exhibit 10.1. This is a classic unregistered equity issuance to private investors. For a small-cap biotech company like Polaryx Therapeutics, a private placement is material as it signals capital raising, potential dilution to existing shareholders, and the company's liquidity position.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:42:51.845064+00:00","company_name":"Polaryx Therapeutics, Inc.","ticker":"PLYX","filing_date":"2026-05-28"}]}